Search results for: 'PFRO - Pharmaceutical Clinical Contract Peripheral Services Landscape, Forecast to 2030'

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

16 Aug 2016  |  North America  |  Market Research

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Emerging Business Models Drive Transformation

Infographics

×

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to comme...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

This research service presents an overview and analysis of the Latin American Contract Research Organization (CRO) market with a focus on Argentina, Brazil, and Mexico. It provides country revenue by phase, therapeutic type, and region. The study discusses key challenges and emerging market trends, while providing detailed information on support se...

More than 6,000 molecules are currently in clinical development across the pharmaceutical research and development (R&D) landscape, with more than 11,000 in the preclinical phase. The industry is witnessing the growth of small- to mid-segment pharma/biotech players making significant contributions to drug discovery and development pipelines. Across...

This report examines the expanding role of smart contracts in city services, beginning with a foundational overview of blockchain technology and smart contracts, including their core principles and applications across various industries. Anchored by Frost & Sullivan’s top three strategic imperatives, the report examines how these technologies are r...

This outlook identifies the trends shaping the global pharmaceutical landscape. The growth of the global pharmaceutical industry will plateau in 2023 due to a slowdown of the biologics segment as a result of a decrease in the uptake of COVID-19 vaccines and therapeutics. Market growth will be low in the United States and Europe and highest in the A...

09 May 2025  |  Global  |  Market Research

Peripheral Vascular Devices Industry, Global, 2024–2029

Innovations in Drug-eluting Stents and Drug-coated Balloons are Driving Transformational Growth

Infographics

×

Frost & Sullivan observes that the shift to drug-eluting stents and drug-coated balloons will be the key trends driving the peripheral vascular devices industry during the forecast period. Investments in bioresorbable scaffolds will further drive the market growth. Drug-eluting bioresorbable scaffolds are an area of interest among industry stakehol...

Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generation of evidence to support the drug’s value proposi...